Accessibility Menu
 

Eucrates Biomedical Acquisition Corp.

(NASDAQ) EUCR

Current PriceN/A
Market CapN/A
Since IPO (2020)+0%
5 YearN/A
1 Year+1%
1 Month-2%

Eucrates Biomedical Acquisition Corp. Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$0.00

Net Income (TTM)

$5.44M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

EUCR News

No articles available.

EUCR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Eucrates Biomedical Acquisition Corp.

Industry

Capital Markets

Employees

4

CEO

Parag Phoolchand Saxena, MBA

Headquarters

New York City, NY 10019, US

EUCR Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

10%

Return on Capital

-6%

Return on Assets

44%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Short Interest

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

$699.00K

EBITDA

$2.58M

Operating Cash Flow

$630.29K

Capital Expenditure

$0.00

Free Cash Flow

$630.29K

Cash & ST Invst.

$18.86K

Total Debt

$60.06K

Eucrates Biomedical Acquisition Corp. Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/A

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

$546.70K

-81.1%

EBITDA

$26.23K

-102.2%

Quarterly Fundamentals

Name
Q4 2022YOY CHG

Net Cash

$41.20K

-183.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

44.36%

N/A

Return on Invested Capital

-5.63%

N/A

Free Cash Flow

$391.18K

-17.1%

Operating Cash Flow

$391.18K

-17.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FMIVForum Merger IV Corporation
$10.35-0.10%
FNVTFinnovate Acquisition Corp.
$11.62+100.00%
PTWOUPono Capital Two, Inc.
$12.00+11.21%
BRACUBroad Capital Acquisition Corp.
$12.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
SMCISuper Micro Computer
$20.53-0.33%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.82+0.06%

Questions About EUCR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.